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In 2015, nearly 3 in 5 women aged 50-69 years had access to a free-of-charge 
mammography screening within one of the ten organized programmes in Swit-
zerland.  
The outcomes of 8 programmes monitored across the years 2010-2015 show a 
stable quality of mammography performance, largely in line with the indicator 
values recommended by the European Guidelines. However, a substantial het-
erogeneity of performance subsists across programmes. 
The participation rate in organised screening is slightly below 50 percent and 
has decreased in the more recent years due to the inclusion of a large new pro-
gramme with a relatively low participation. The participation of longer running 
programmes, however, is rather stable.  
It is recommended to monitor annually the Swiss organized mammography 
screening programmes. This will support improved recording of follow-up data 
and lead to more routine in extracting appropriate monitoring data from the 
information system.  
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Summary 
This fourth national monitoring report for Swiss Cancer Screening shows the results of organised mammogra-
phy screening in Switzerland for the years 2010-2015, subdivided into two triennial periods, 2010-2012 and 
2013-2015, respectively.  
The number of regional programmes increased from 7 in 2010 to 10 in 2015, currently covering the geograph-
ical area of 12 cantons. In 2015, 56.5 percent of the 50-69 years old women in Switzerland lived in an area 
covered by a breast cancer screening programme, nearly a doubling of coverage since 2010.  
The results in this monitoring report are based on available data from 7 programmes (VD, VS, GE, FR, BEJUNE, 
SG-GR, TG) in the period 2010-2012 and from 8 programmes (with BE) in the period 2013-2015. The coverage 
by invitation rate increased from 91% in 2010-2012 to 98% in 2013-2015. Almost 290,000 from the 680,000 
eligible women in 2013-2015 attended for screening, resulting in a participation rate of 42.5%. The participa-
tion decreased by more than 4% compared to 2010-2012, mainly due to the low participation in the large new 
programme of Canton of Bern. Similar decreases between the two triennial periods were found in the first 
round participation (32.9% vs. 38.3%) and in the reattendance of the women who participated in the previous 
round (81.7% vs. 85.6%). Without Bern, the overall participation rate was stable around 47% and the first 
round participation around 38-39%. Participation rates are likely slightly underestimated, as some participa-
tion records could not be extracted from the new information system MC-SIS.  
Prevalent screening in 2013-2015 led to a recall rate (73.0 per 1000 women screened) slightly higher than 
recommended by the European Guidelines but substantially lower than in 2010-2012 (86.9 per 1000). The main 
consequence of the reduced recall rate is a substantially lower false-positive rate (67 vs. 80 per 1000). There 
is a concomitant but less pronounced decrease in breast cancer detection (6.1 vs. 6.9 per 1000) given the 
slightly increased positive predictive value of the screening examination (8.4% vs. 8.0%). Although the classi-
fications of tumour characteristics are partly incomplete, most tumour distribution proportions are in accord-
ance with the European Guidelines.  
The results of incident screening in 2013-2015 and 2010-2012 were quite similar, with exception of a somewhat 
lower breast cancer detection rate (4.5 vs. 5.1 per 1000). These results were close to or fully in line with the 
desirable values recommended by the European Guidelines. The variation in results of the regional pro-
grammes was much smaller than in prevalent screening.  
The most important consequences for screened women, e.g. the chance to be recalled and to get a false- or 
true-positive screening result, hardly differed between the two time periods. This points to a stable perfor-
mance of Swiss breast cancer screening programmes over time.  
It is recommended to monitor annually the Swiss organized mammography screening programmes. This will 
support improved recording of follow-up data and lead to more routine in extracting appropriate monitoring 
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This fourth national monitoring report for Swiss Cancer Screening shows the results of organised 
mammography screening in Switzerland for the years 2010-2015. The shift towards a new infor-
mation system in the last years and difficulties in extracting data for analytical purpose led to an in-
terruption of the annual monitoring for some years1. In 2018, data became available again for moni-
toring the period 2010 up to and including 2015. However, the accessibility of older screening data in 
the new information system is not complete and led to the loss of an estimated 4 percent of screen-
ing and follow-up records. Although this loss appears to be non-selective, slight differences in out-
comes of regional programmes com-
pared to the previously published re-
ports across the years 2010, 2011 and 
2012 occur. Because data from the joint 
programme of the Cantons of St.Gallen 
and Graubünden could be included for 
the first time in this fourth monitoring 
report, national outcomes as of 2011 
are not comparable anymore with 
those of previous reports.  
In this report, national results are presented for the 3-year period 2013-2015 in comparison with the 
previous triennial period 2010-2012. This approach leads to more stable results as they are based on 
larger numbers. Also, the presentation of the outcomes may become easier to follow.  
Methods 
Data for this monitoring report were extracted from the MC-SIS database that is used by all regional 
programmes. Records of all women were included in this monitoring report who had an invitation 
letter for a screening examination or had requested a screening examination between 2010 and 
2015, and at the moment of invitation were at least 50 years old and not older than 70 years, were 
living in the recruitment area of a regional programme, did not have a prior breast cancer, were not 
seriously ill, and did not have a breast prosthesis.  
All variables were checked for completeness and consistency. Synchronous events, such as a recall 
for multiple suspect findings or a multiple breast cancer diagnosis were counted as one event per 
woman’s screening round, and per woman, respectively. In case of multiple breast cancers, the tu-
mour with the highest stage was considered. Indicators were calculated for regional programmes and 
the national total according to the Monitoring proposal of Swiss Cancer Screening2 that is mainly 
based on the European Guidelines for Quality Assurance3. All indicators were independently double-
checked and their values compared with the standards recommended by the European Guidelines.  
  
                                                          
1 When extracting the monitoring data from the MC-SIS database, some data could not be well accessed lead-
ing to missing values for several variables. This might in particular affect figures on coverage and participation 
leading to an underestimation of these indicators. 
2 Swiss Cancer Screening. National monitoring of organized mammography screening programmes in Switzer-
land. Proposal. Bern: Swiss Cancer Screening, rev. 24.0 from 15.12.2017. 
3 Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L and Puthaar E (eds.). European Guidelines 
for Quality Assurance in breast cancer screening and diagnosis. Fourth Edition. Luxembourg: Office for Official 
Publications of the European Communities, 2006.  
Why a national report? 
A national monitoring gives the opportunity to assess at the 
same moment and in a uniform way the performance of Swiss 
regional programmes. Predefined outcome and quality indica-
tors are identically calculated. This contributes to the harmoni-
sation of quality assurance and the uniform evaluation of the 
process and outcomes of the screening programmes.  
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Breast cancer screening in Switzerland  
At the beginning of 2015 slightly over 1 million women aged 50-69 years lived in Switzerland. Of 
these women, the target population for breast cancer screening, 56.5 percent lived in a canton with a 
screening programme, nearly twice as much as in 2010 (Figure 1). The largest increase in population 
coverage occurred in 2013 with the start of the programme in the Canton of Bern, the second most 
populated Swiss canton.  
 
Figure 1 
Swiss (CH) coverage of target popula-
tion (women aged 50-69 years) by re-
gional breast cancer screening pro-








Breast cancer screening is organized and carried out per canton or region. By 2010, programmes 
were fully implemented for years in the French-speaking Cantons of Vaud (VD), Valais (VS), Geneva 
(GE), Fribourg (FR) and the region BEJUNE (this programme covers the French-speaking part of the 
Canton of Bern and the Cantons of Jura and Neuchâtel) but there was no joint monitoring. In 2010, 
the first two programmes from the German-speaking cantons of St.Gallen and Thurgau were imple-
mented , followed by the Canton of Graubünden (GR) in 2011, the German-speaking part of the Can-
ton of Bern (BE) in 2013, the half Canton of Basel-Stadt (BS) in 2014, and the Canton of Ticino (TI) in 
2015 (Figure 2). Mammography screening in the Cantons of St.Gallen and Graubünden is delivered by 
the same organisation and considered as one programme (SG-GR) for the national monitoring.  
As agreed by Swiss Cancer Screening, new programmes contribute the first time to the Swiss moni-
toring in the calendar year in which they were active during the whole year and have completed a full 
screening round (2011 for Thurgau, St.Gallen and Graubünden; 2014 for Bern; 2016 only for Basel-
Stadt and Ticino).  
In the period 2010-2012 contributed five to seven (TG and SG-GR as of 2011) programmes to the 
Swiss monitoring and in the period 2013-2015 seven to eight (BE as of 2014) programmes. This 
means that new programmes were implemented during both time periods. The integration of new 
programmes leads to differences across years in the distribution of womens’ ages and in that of ini-
tial (prevalent) and subsequent (incident) screening examinations. One has to realise that both age 
and the kind of screening examination have impact on the outcomes of breast cancer screening. In a 
non-steady-state situation of screening, as it was the case in Switzerland during 2010-2015, the com-
parison of outcomes between different calendar years or time periods must be interpreted with cau-
tion (Appendix 1). For the same reason, trends over the total six year-period cannot easily be de-
scribed.  
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Figure 2 
Swiss geographical coverage 
by regional breast cancer 
screening programmes (year of 








Screening activities (Table 1) 
In the period 2013-2015, the eight regional programmes invited 683,732 women for screening and 
performed 277,896 screening mammographies within the 3-year period (Table 1, Activity statistics). 
Invitational activities increased by more than half compared to 2010-2012, whereas the increase in 
the number of women screened was about a third.  
The largest programme has invited and screened approximately three times more women than the 
smallest one. The magnitude of the variation in absolute numbers across programmes does however 
not reflect that programmes were not all active during the whole 3-year-period.  
The activity figures do not provide a participation rate, because the reported invitations and screen-
ing examinations are not necessarily linked to each other. Some women will attend only in the year 
following the year of invitation. A screening mammography at the beginning of 2013 (and falling in 
the period 2013-2015) may thus be the result of an invitation in 2012 (period 2010-2012). Some 
women invited in 2015 will participate in 2016, i.e. beyond the period covered by this report.  
Coverage and participation rates (Table 1) 
Around 4500 (0.3%) from the 1,4 million women targeted in 2013-2015 were excluded (Table 1, Cov-
erage and participation rates). As a woman 
is invited every second year, only about half 
of the eligible women at the beginning of a 
calendar year will be invited during this 
same year; the other half will be invited in 
the following year. From the 696,111 eligi-
ble women in 2013-2015, 679,261 were in-
vited which results in a coverage by invita-
tion rate of 97.6 percent. This rate is higher 
than in 2010-2012 (90.6%).  
Coverage rate  
The coverage rate gives the proportion of targeted women that 
in a defined time period has been invited (coverage by invita-
tion) or screened (coverage by participation).  
Ideally, the latter should include screening mammographies 
performed outside the organised programme, but no reliable 
data are available on this so-called opportunistic screening in 
Switzerland.  
The coverage by invitation rate measures the equal access to 
mammography screening for all entitled women.  
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One might tend to think that the ideal coverage by invitation rate would be precisely 100 percent. 
But the target population is a dynamic population continuously altered by immigration into and emi-
gration out of the catchment area of a programme. Also, depending on when women are invited dur-
ing the year, this can lead to both a higher or lower coverage rate than 100 percent. Furthermore, 
some women opt out of a programme, or become ineligible in subsequent screening resulting in a 
decreased number of invited women.  
 
Table 1 Activity statistics, coverage and participation rates 2010-2012 and 2013-2015, and minimum (min.) and maxi-
mum (max.) value of the regional programmes within the corresponding time period 
Nearly 290,000 women invited in 2013-2015 attended the programme within one year after getting 
the invitation letter (Table 1, Coverage and participation rates). This results in a participation rate of 
42.5 percent. Compared to 2010-2012, the participation rate decreased by 4.4 percent. The main 
reason is the rather low participation in the new programme in Bern (25.6%) that has a strong impact 
given the relatively large size of the invited population. Furthermore, the participation rates might be 
somewhat underestimated because of a limited accessibility to some mammography events (see 
Footnote 1).  
The first round participation rate of 32.9 
percent in 2013-2015 was substantially 
lower than in 2010-2012 (38.3%). This 
rate is strongly influenced by the pro-
gramme in Bern that in the first round in-
vited women of all ages. The large pro-
portion of first invited older women with 
a relatively lower participation had a 
negative impact on the first round partic-
ipation rate.  
The reattendance rate gives the partici-
pation compliance of women who have 
been screened in the previous round. 
This rate is with 81.7 percent in 2013-
2015 slightly lower than in the period 
2010-2012 (85.6%).  
Participation rate (within 1 year following the invitation) 
The participation rate within 1 year measures the proportion of 
eligible women that attended the programme within one year af-
ter having been invited for a screening examination. It does not 
matter, if the examination takes place in another year than the 
year in which the woman has been invited.  
The participation rate within 1 year must not be confused with the 
activity index specified in the annual reports of the regional pro-
grammes. This index reports the number of performed screening 
examinations divided by the number of invitations sent out within 
the same calendar year. For this reason, the rate of the activity in-
dex can substantially differ from the participation rate.  
Reattendance rate 
The reattendance rate measures the proportion of women that 
participates in the current screening round who also participated 
in the previous screening round (within three years prior to the 
current invitation). 
Activity statistics 2010-2012 min. max. 2013-2015 min. max.
Target population (programs in monitoring) 958,196 60,613 251,279 1,396,693 99,115 266,956
Women invited (incl. self-referrals) 435,309 32,580 113,913 683,732 47,731 136,382
Women screened 201,952 11,779 58,528 277,896 20,051 59,782
Coverage and participation rates 2010-2012 min. max. 2013-2015 min. max.
Eligible women invited 432,720 32,230 113,359 679,261 47,381 135,193
Women screened (within 1 year) 202,931 12,293 57,439 289,005 19,909 62,578
Coverage by invitationa 90.6% 88.0% 107.0% 97.6% 94.0% 105.6%
Participation ratea 46.9% 31.3% 59.6% 42.5% 25.6% 59.8%
1st round participation rate
a 38.3% 27.8% 52.7% 32.9% 25.9% 50.9%
Reattendance
a 85.6% 74.3% 89.2% 81.7% 67.4% 89.0%
a
 based on eligible population per year
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When excluding the data from Bern, participation rates appear to be rather stable: the overall partic-
ipation would be 46.7 percent (46.9% in 2010-2012) and the first round participation rate would be-
come with 39.2 percent slightly higher than in 2010-2012 (38.3%). When considering only the five 
first programmes that are in a steady state situation as of 2011, reattendance rates were similar be-
tween the two time periods (85.6% and 85.5%, respectively).  
Results of mammography screening  
Prevalent screening (Table 2a) 
In the period 2013-2015, some one hundred thousand women underwent a prevalent screening 
mammography, that is 36.0 percent of all 277,896 women screened within this time period. Some 
7,308 women were recalled for a diagnostic assessment, resulting in a recall rate of 73.0 per 1000 
screens (Table 2a). This rate is slightly higher than the acceptable level of 70 per 1000 recommended 
by the European Guidelines.  
The screening led to the detection of 609 breast cancers or 6.1 per 1000 prevalent screens. The posi-
tive predictive value of mammography screening (PPV) was 8.4 percent; that means that one in 12 
women with a positive examination is diagnosed with a breast cancer. The false-positive rate was 
66.9 per 1000 prevalent screens. Compared with the period 2010-2012, 14 per 1000 less women 
have been recalled in the most recent period. The main consequence of this lower recall rate was a 
relative reduction of 16 percent of the false-positive rate (66.9 vs. 80.0 per 1000) with a simultane-
ous relative decrease of the breast cancer detection by 12 percent (6.1 vs. 6.9 per 1000), resulting in 
a marginally higher PPV in the period 2013-2015. 
  
Prevalent and incident screening 
When screening a population for the first time, one should find a large number of asymptomatic cancers (cancers in a 
preclinical phase). A perfect screening test would theoretically detect all these prevalent cancers. For this reason, a first 
(initial) screening test is also called prevalent screening. Prevalent screening leads to relatively high recall and breast 
cancer detection rates. The positive predictive value of the mammography, however, is lower than in incident screens, 
because of the lack of the opportunity to compare the current mammogram with previous ones, what results in high 
false-positive rates. 
In subsequent screening rounds, less asymptomatic cancers will be detected because many have already been found 
during the prevalent round. Subsequent screening mainly detects cancers that have become preclinically detectable since 
the previous screening round, the so called incident cases. Therefore, subsequent screening is also called incident screen-
ing.  
In the first two years of a mammography screening programme, only prevalent screening examinations are performed 
within the total age range of targeted women. In an older programme, the vast majority (more than 80%) of all screens 
is an incident screen. The prevalent screens are mainly performed among young women who reach 50 years of age and 
newly belong to the target population. 
Because results importantly differ between prevalent and incident screens, they are presented separately. This is partic-
ularly relevant when the distribution of prevalent and incident screens shows large variations across time periods (see 
Appendix 1).  
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Table 2a Results prevalent screening 2010-2012 and 2013-2015, and minimum (min.) and maximum (max.) value of 
the regional programmes within the corresponding time period 
 There is a large variation in the mentioned indicators between regional programmes; this variation is 
also substantially larger than in 2010-2012. A recall rate or a false-positive rate above 100 per 1000 
prevalent screens must be considered much too high. This means that at least 1 out of every 10 first 
screened women is recalled or has a false-positive result.  
In programmes with a high participation 
and a low level of opportunistic screen-
ing, a breast cancer detection of less 
than 5 per 1000 prevalent screens and a 
PPV of 4.6 percent would be considered 
as too low. According to the European 
Guidelines, the detection rate in preva-
lent screening should be at least the 
threefold of the underlying breast can-
cer incidence rate (IR) for the corre-
sponding ages. However, this standard 
assumes no screening prior to organised 
screening and it is not easy to decide the 
Recall rate, false-positive rate, breast cancer detection rate and 
positive predictive value of the screening test (PPV) 
The recall rate gives the proportion of screened women that is re-
called for diagnostic assessment due to a suspect mammographic 
finding (“screen-positive” women).  
The false-positive rate gives the proportion of screened women in 
whom the clinical assessment after being recalled did not result in 
a breast cancer diagnosis.  
The breast cancer detection rate gives the proportion of screened 
women diagnosed with breast cancer after being recalled for clini-
cal assessment (“true-positive” result of screening).  
The positive predictive value of the screening test (PPV) measures 
the proportion of recalled (screen-positive) women that is diag-
nosed with breast cancer during the clinical assessment.  
Screening tests performed 2010-2012 min. max. Eur.GL 2013-2015 min. max.
Prevalent (first) mammographies 72,289 5,754 21,181 100,070 5,725 30,889
Referrals 2010-2012 min. max. Eur.GL 2013-2015 min. max.
Recalled women 6,281 473 2,064 7,308 296 1,929
Recall rate (per 1000 screens) 86.9 58.1 103.8 <70 (<50) 73.0 44.0 109.4
Completeness follow-up referrals 99.9% 99.4% 100.0% 99.2% 98.3% 100.0%
False-positive rate (per 1000 screens) 80.0 52.3 96.6 66.9 38.9 101.8
Breast cancer detection rate (/1000) 6.9 5.8 8.0 (>)3 x IR 6.1 4.6 7.5
Positive predictive value (PPV adjusteda) 8.0% 6.2% 10.0% 8.4% 4.6% 11.8%
Screen-detected breast cancers 2010-2012 min. max. Eur.GL 2013-2015 min. max.
Screen-detected breast cancers (N) 499 35 170 609 34 174
Tumour (pT) size determined 95.4% 84.3% 100.0% 89.5% 75.0% 99.4%
Lymph nodal status (pN) determined 77.0% 64.7% 83.5% 64.9% 35.3% 80.0%
Tumour behaviour determined 96.6% 86.3% 100.0% 83.7% 43.6% 100.0%
Ductal carcinoma in-situ (DCIS) 19.6% 11.4% 26.1% 10% (10-20%) 18.9% 8.3% 30.6%
Invasive breast cancers (N) 384 27 131 395 24 129
  -  invasive node-negative cancers 80.5% 76.8% 87.9% NA (>70%) 78.0% 73.2% 85.2%
  -  invasive cancers < 10 mm (T1a+T1b) 28.9% 18.9% 45.5% NA (>25%) 29.1% 17.9% 59.3%
  -  invasive cancers < 15 mm 39.6% 26.5% 55.4% 50% (>50%) 47.8% 28.6% 66.7%
Early stage breast cancers (stage 0+I) 61.5% 48.1% 70.6% NA (>70%) 64.0% 55.8% 73.5%
Advanced stage breast cancers (st. II+) 34.3% 15.7% 50.6% NA (<30%) 25.9% 16.7% 34.5%
Stage undetermined 4.2% 0.0% 13.7% 10.0% 0.6% 25.0%
a
 based on known follow-up only Eur.GL: European Guidelines recommendations
Acceptable level (Desirable level)
IR: (underlying) cancer incidence rate
NA: not applicable
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underlying incidence in presence of long-standing organised and/or widespread opportunistic 
screening. 
The characteristics of the screen-detected breast cancers cannot easily be interpreted given the rela-
tively low percentages of determined tumour size (<90%), tumour behaviour (<84%), lymph nodal 
status (<65%) and tumour stage (90%) (Table 2a, Screen-detected breast cancers). However, most in-
dicators of early detection are in accordance with the European Guidelines. A 19 percent ductal carci-
noma in-situ (DCIS) as such is a reasonable proportion, but the definite result depends on how many 
DCIS are contained in the group with undetermined tumour behaviour. For the same reason, the pro-
portion of early or advanced tumour stages might be underestimated based on data currently availa-
ble. The large variation in missing information, in particular together with a relatively small number 
of screen-detected breast cancers can lead to unstable and unreliable proportions of tumour sizes 
and stages. 
Incident screening (Table 2b) 
 
Table 2b Results incident screening 2010-2012 and 2013-2015, and minimum (min.) and maximum (max.) value of the 
regional programmes within the corresponding time period 
 Seventy percent of the 177,826 incident (subsequent) screening mammographies in 2013-2015 were 
performed within a time interval of 22 to 26 months after the previous screen (Table 2b, Screening 
Screening tests performed 2010-2012 min.* max.* Eur.GL 2013-2015 min.$ max.$
Incident (subsequent) mammographies 129,663 15,723 46,957 177,826 12,746 47,467
subsequent screens within 22-26 months 72.0% 70.0% 80.2% 70.2% 63.6% 81.1%
Referrals 2010-2012 min.* max.* Eur.GL 2013-2015 min.$ max.$
Women recalled 4,449 537 1,528 5,894 430 1,986
Recall rate (per 1000 screens) 34.3 24.2 53.9 <50 (<30) 33.1 17.9 43.9
Completeness follow-up referrals 100.0% 99.9% 100.0% 99.3% 99.0% 99.8%
False-positive rate (per 1000 screens) 29.2 19.0 48.8 28.6 13.2 39.6
Breast cancer detection rate (/1000) 5.1 5.0 5.2 (>)1.5 x IR 4.5 3.8 5.4
Positive predictive value (PPV adjusted
a
) 14.9% 9.4% 21.2% 13.8% 10.0% 26.2%
Screen-detected breast cancers 2010-2012 min.* max.* Eur.GL 2013-2015 min.$ max.$
Screen-detected breast cancers (N) 661 80 235 808 49 255
Tumour (pT) size determined 94.7% 90.6% 100.0% 93.9% 80.3% 100.0%
Lymph nodal status (pN) determined 79.0% 71.1% 87.5% 77.0% 68.4% 83.3%
Tumour behaviour determined 95.5% 91.9% 100.0% 95.0% 81.2% 100.0%
Ductal carcinoma in-situ (DCIS) 16.5% 10.0% 21.1% 10% (10-20%) 18.1% 12.8% 22.4%
Invasive breast cancers (N) 522 70 182 622 38 198
  -  invasive node-negative cancers 82.2% 76.3% 91.2% (>)75% 78.1% 75.0% 84.2%
  -  invasive cancers < 10 mm (T1a+T1b) 32.8% 27.4% 37.1% >25% (>30%) 33.4% 23.7% 42.9%
  -  invasive cancers < 15 mm 54.8% 45.7% 61.5% 50% (>50%) 54.3% 44.1% 62.6%
Early stage breast cancers (stage 0+I) 70.8% 66.3% 76.0% 75% (>75%) 67.9% 56.4% 74.6%
Advanced stage breast cancers (st. II+) 23.9% 21.3% 30.0% 25% (<25%) 26.6% 22.8% 34.7%
Stage undetermined 5.3% 0.0% 9.4% 5.4% 0.0% 19.7%
* incident screens SG-GR 2012 (N=326) excluded Eur.GL: European Guidelines recommendations
$ incident screens BE 2015 (N=1131) excluded Acceptable level (Desirable level)
a
 based on known follow-up only IR: (underlying) cancer incidence rate
NA: not applicable
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examinations performed). Due to a subsequent screen, 5,894 women were recalled for a diagnostic 
assessment and 808 breast cancers were detected. This results in a recall rate of 33.1 per 1000 inci-
dent screens close to the desirable level recommended by the European Guidelines, a breast cancer 
detection rate of 4.5 per 1000, a positive predictive value of mammography screening (PPV) of 13.8 
percent, and a false-positive rate of 28.6 per 1000. These outcomes are similar to those in the period 
2010-2012, with exception of a somewhat lower breast cancer detection rate (4.5 vs. 5.1 per 1000). 
The variation between regional programmes is modest and does not present extreme outliers.  
In contrast to the prevalent screens, tumour characteristics are more complete, particularly for the 
period 2013-2015 (Table 2b, Screen-detected breast cancers). Of the 808 screen-detected cancers, 
18.1 percent was a ductal carcinoma in-situ and 77.0 percent an invasive breast cancer; 67.9 percent 
of breast cancers were detected in an early stage (stage I) and 26.6 percent in an advanced stage 
(stages II+). Of invasive cancers, four out of five presented without lymph node involvement, one 
third was smaller than 10 mm in size, and more than half smaller than 15 mm.  
The distribution of screen-detected breast cancers was mostly in line with the desirable levels recom-
mended by the European Guidelines and quite similar to that in the period 2010-2012. One regional 
programme had a relatively large proportion of undetermined tumour behaviour and tumour stage; 
as a consequence the proportions of DCIS and early-stage cancer seem to be too low. Otherwise, no 
proportions in regional programmes differed remarkably from the national means.  
Main consequences for women participating in mammography screening (Figure 3)  
Women should know about the potential consequences when they participate in mammography 
screening. The chance of being recalled for diagnostic assessment, being diagnosed with a breast 
cancer (true-positive result) or having a false-positive result of the screening examination are esti-
mated and presented in this report. The currently available data do not contain sufficient infor-
mation on clinical diagnostic assessment and no information on interval cancers (cancer diagnosed 
after a negative mammography and before the next due screen).  
Figure 3 shows the rates of recall, true- and false-positive results per 1000 women aged 50-51 under-
going a first (prevalent) screening examination (Figure 3A) and per 1000 women of all ages with a 
subsequent (incident) screen (Figure 3B). The focus on 50-51 year old women in prevalent screening 
(Figure 3A) improves the comparability across programmes with varying years of operation (see box 
Prevalent and incident screening). For this same reason, the incident screening rates in Figure 3B are 
based on the five regional programmes (VD, VS, GE, FR, BEJUNE) being in a steady state situation as 
of 2011. The rates do not differ much during the two time periods, though they were minimally in-
creased in the young first invited and screened women in period 2013-2015 but rather stable in inci-
dent screens.  
Young women with a prevalent screening examination have a higher likelihood than the total 
screened population to be recalled and to have a false-positive result. This is due to the denser tissue 
of the young breast that makes the interpretation of mammographic findings more difficult, the 
more as no previous mammograms are available for comparison. In the following (incident) screen-
ing rounds, however, the chance of a recall and a false-positive result will be remarkably lower for 
these women.  
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Figure 3 
Likelihood per 1000 women of a recall, 
true-positive result (screen-detected 
breast cancer) or false-positive result in 
mammography screening in 2010-2012 and 
in 2013-2015 for 
A: first screened women aged 50-51 years 
(prevalent screens; excl. data SG-GR), 
and 
B: subsequently screened women aged 
50-69 years (incident screens; regional 
programmes in steady state situation: 




















APPENDIX 1 shows how ages and types of screening round are distributed depending on the imple-
mentation status of the regional programmes.  
In APPENDIX 2, the main national outcomes are specified by calendar year between 2010 and 2015.  
 
APPENDIX 1 Distribution of ages and screening examinations in prevalent and incident rounds 
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Age distribution 
In the first round of a programme, the total eligible population, e.g. all women aged 50 to 69 years, are in-
vited for a prevalent screening examination. In the next invitation rounds, the great majority of first invited 
women is 50 years old; the small proportion of older women are those who immigrated into the catchment 
area of the programme after the previous round. As the occurrence of breast cancer is age-dependent, a 
prevalent screening round will result in higher recall and detection rates when the proportion of screened 
elderly women increases.  
Figure 4 shows the annual difference in age distribution of screened women in the prevalent round be-
tween all programmes (Figure 4A) and the 5 regional programmes in a steady state situation as of 2011 
(VD, VS, GE, FR and BEJUNE; Figure 4B).  
Figure 4 Age-distribution of initially screened women (prevalent screening), 2010-2015; 
 A: all programs; B: regional programmes in steady state situation (VD, VS, GE, FR, BEJUNE)  
 
More than 90 percent of the women who have a first screening mammography is younger than 55 years in 
the steady state situation, whereas this proportion falls to 60 percent when prevalent screens are mixed up 
between first and later screening rounds. This was the case in 2011 and 2012 with the implementation of 
the programmes in TG and SG-GR, and in 2014 with the implementation of the programme in BE. The more 
difficult interpretation of mammography in young women usually leads to higher recall rates in combina-
tion with a lower positive predictive value than in older women. This means that strongly alternating age 
distributions from one time period (calendar year) to another will impact on the outcomes such as recall 
and breast cancer detection rates, making temporal comparison difficult.  
Distribution of screening examinations 
More than 80 percent of the screening examinations is a subsequent (incident) screen in the second or fur-
ther screening rounds. In subsequent screens, less breast cancers are detected than in prevalent screens. A 
higher proportion of subsequently screened women in one calendar year may lead to a lower breast cancer 
detection rate compared to years with relatively less subsequent screens.  
Figure 5 shows the annual difference in distribution of prevalent (initial) and incident (subsequent) screen-
ing examinations between all programmes (Figure 5A) and the 5 programmes in a steady state situation as 
of 2011 (VD, VS, GE, FR and BEJUNE; Figure 5B). Due to the inclusion of first round (prevalent) screening 
examinations in the total for all regional programmes, the proportion of prevalent screens varies between 
APPENDIX 1 Distribution of ages and screening examinations in prevalent and incident rounds 
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20 and 35 percent and reflects as in Figure 4A the implementation of new programmes. This proportion is 
much lower in the steady state situation and stable around 15 percent.  
Figure 5 Distribution of initial (prevalence) and subsequent (incidence) screening examinations, 2010-2015; 
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Activity statistics 2010 2011 2012 2013 2014 2015 2010-2015 2010-2012 2013-2015
Target population (programs in monitoring) 239,236 355,564 363,396 371,190 507,473 518,030 2,354,889 958,196 1,396,693
Women invited (incl. self-referrals) 115,100 151,454 168,755 175,853 251,113 256,766 1,119,041 435,309 683,732
Women screened (within 1 year) 55,107 70,493 76,352 81,003 96,112 100,781 479,848 201,952 277,896
Coverage and participation rates 2010 2011 2012 2013 2014 2015 2010-2015 2010-2012 2013-2015
Eligible women invited 114,347 150,672 167,701 174,694 249,078 255,489 1,111,981 432,720 679,261
Screenees (within 12 months) 55,438 71,180 76,313 83,916 100,955 104,134 491,936 202,931 289,005
Coverage by invitation
a 95.9% 84.9% 92.6% 94.4% 98.6% 98.9% 94.7% 90.6% 97.6%
Participation ratea 48.5% 47.2% 45.5% 48.0% 40.5% 40.8% 44.2% 46.9% 42.5%
1st round participation rate
a 42.8% 38.1% 37.1% 38.6% 30.1% 33.1% 35.1% 38.3% 32.9%
Proportion 1st round participation a 27.0% 37.6% 40.5% 34.0% 37.2% 36.5% 35.9% 35.8% 36.0%
Reattendancea 84.2% 85.4% 87.1% 79.5% 82.2% 83.1% 83.3% 85.6% 81.7%
Screening results
Screening tests performed 2010 2011 2012 2013 2014 2015 2010-2015 2010-2012 2013-2015
Women screened 55,107 70,493 76,352 81,003 96,112 100,781 479,848 201,952 277,896
 - Prevalent (first) mammographies 14,856 26,534 30,899 27,504 35,780 36,786 172,359 72,289 100,070
    % 27.0% 37.6% 40.5% 34.0% 37.2% 36.5% 35.9% 35.8% 36.0%
 - Incident (subsequent) mammographies 40,251 43,959 45,453 53,499 60,332 63,995 307,489 129,663 177,826
    % 73.0% 62.4% 59.5% 66.0% 62.8% 63.5% 64.1% 64.2% 64.0%
    % subsequent within 22-26 months 71.6% 71.7% 72.6% 70.9% 70.1% 69.8% 71.0% 72.0% 70.2%
Recalls 2010 2011 2012 2013 2014 2015 2010-2015 2010-2012 2013-2015
Women recalled 2,547 4,019 4,164 4,342 4,294 4,566 23,932 10,730 13,202
Recall rate (per 1000 screens) 46.2 57.0 54.5 53.6 44.7 45.3 49.9 53.1 47.5
Completeness follow-up referrals 100.0% 99.9% 99.9% 99.7% 98.8% 99.3% 99.6% 99.9% 99.3%
False-positive rate (per 1000 screens) 40.3 51.3 48.9 47.9 39.7 40.6 44.5 47.4 42.4
Breast cancer detection rate (/1000) 5.9 5.7 5.6 5.7 5.0 4.7 5.4 5.7 5.1
Positive predictive value (PPV adjustedb) 12.8% 10.0% 10.4% 10.7% 11.3% 10.5% 10.8% 10.8% 10.8%
Screen-detected breast cancers 2010 2011 2012 2013 2014 2015 2010-2015 2010-2012 2013-2015
Screen-detected breast cancers (N) 327 402 431 462 479 476 2,577 1,160 1,417
Tumour (pT) size determined 94.8% 95.0% 95.1% 92.4% 90.6% 93.1% 93.4% 95.0% 92.0%
Lymph nodal status (pN) determined 80.1% 75.6% 78.9% 76.0% 72.0% 67.4% 74.6% 78.1% 71.8%
Tumour behaviour determined 95.7% 96.3% 95.8% 94.4% 91.9% 84.5% 92.8% 95.9% 90.2%
Ductal carcinoma in-situ (DCIS) 15.6% 20.6% 16.9% 18.4% 19.8% 17.0% 18.2% 17.8% 18.4%
Invasive breast cancers (N) 262 304 340 351 345 321 1,923 906 1,017
  -  invasive node-negative cancers 77.9% 84.5% 81.5% 78.3% 77.7% 78.2% 79.7% 81.5% 78.1%
  -  invasive cancers < 10 mm (T1a+T1b) 31.3% 31.9% 30.3% 33.3% 31.3% 30.5% 31.5% 31.1% 31.8%
  -  invasive cancers < 15 mm 49.6% 45.7% 49.7% 54.7% 48.1% 52.6% 50.2% 48.3% 51.8%
Early stage breast cancers (stage 0+I) 63.0% 67.9% 68.7% 66.2% 65.3% 67.2% 66.5% 66.8% 66.3%
Advanced stage breast cancers (st. II+) 31.8% 27.1% 26.9% 26.2% 25.7% 27.1% 27.2% 28.4% 26.3%
Stage undetermined 5.2% 5.0% 4.4% 7.6% 9.0% 5.7% 6.2% 4.8% 7.4%
a  based on eligible population per year
b based on known follow-up only
